BMS 986192

Drug Profile

BMS 986192

Alternative Names: [18F]BMS-986192; Anti-PD-L1 - Bristol-Myers Squibb; BMS-986192

Latest Information Update: 23 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD274 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Clinical Phase Unknown Non-small cell lung cancer

Most Recent Events

  • 01 Apr 2017 Interim pharmacodynamics data from preclinical studies in Cancer presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 01 Jun 2016 Clinical trials in Non-small cell lung cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in Netherlands (IV) (EudraCT2015-004760-11)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top